Association of High-sensitivity Cardiac Troponin T with Mortality and Cardiovascular Events in a Community-based Prospective Study in Beijing

Overview

Journal BMJ Open

Specialty General Medicine

Date 2017 Jun 28

PMID 28652289

Citations 7

Authors

Wenkai Xiao

Ruihua Cao

Yuan Liu

Fan Wang

Yongyi Bai

Hongmei Wu

Ping Ye

Affiliations

Soon will be listed here.

Abstract

Objective: The prognostic value of cardiac troponins in apparently healthy populations is not well established. The aim of this study was to investigate the prognostic properties of high-sensitivity cardiac troponin T (hs-cTnT) for long-term adverse outcomes.

Setting: A community-dwelling prospective survey of residents from two communities in Beijing.

Participants: From September 2007 to January 2009, 1680 participants were initially enrolled. Of these, 1499 (870 females, mean age: 61.4 years) participants completed the survey and were followed up for a median of 4.8 years (IQR: 4.5-5.2).

Outcome Measures: The primary outcome was the occurrence of all-cause mortality and major cardiovascular events.

Results: Overall, 820 individuals (54.7%) had detectable hs-cTnT levels. During the follow-up, 52 participants (3.5%) died, 154 (10.3%) had major cardiovascular events and 99 (6.6%) experienced new-onset coronary events. Compared with those with undetectable hs-cTnT levels, participants with hs-cTnT levels in the highest category (≥14 ng/L) had a significantly increased risk for all-cause mortality (adjusted HR (aHR): 2.07, 95% CI 1.05 to 3.01), major cardiovascular events (aHR: 3.27, 95% CI 1.88 to 5.70) and coronary events (aHR: 4.50, 95% CI 2.26 to 9.02) in covariate-adjusted analyses. No differences in stroke incidence were found (aHR: 1.27, 95% CI 0.69 to 2.62). Also, significant associations were presented when hs-cTnT levels were modelled as a continuous variable and when analysing changes in hs-cTnT levels over time with adverse outcomes. The addition of troponin T levels to clinical variables led to significant increases in risk prediction with a marked improvement in the C-statistics (p=0.003 or lower).

Conclusions: In this cohort of individuals from a community-based population, cTnT levels measured with a highly sensitive assay were associated with increases in the subsequent risk for all-cause mortality and major cardiovascular events. These results might support screening for at-risk individuals.

Citing Articles

Association between high-sensitivity cardiac troponin T levels and incident stroke in the elderly Japanese population: Results from the Tohoku Medical Megabank Community-based Cohort Study.

Kobayashi T, Nasu T, Satoh M, Kotozaki Y, Tanno K, Asahi K Am Heart J Plus. 2024; 22:100212.

PMID: 38558906 PMC: 10978419. DOI: 10.1016/j.ahjo.2022.100212.

Joint effect of highly-sensitive cardiac troponin T and ankle-brachial index on incident cardiovascular events: The MESA and CHS.

Tedla Y, Driver S, Szklo M, Kuller L, Lima J, Michos E Am J Prev Cardiol. 2023; 13:100471.

PMID: 36873803 PMC: 9975219. DOI: 10.1016/j.ajpc.2023.100471.

A comparison of echocardiographic and circulating cardiac biomarkers for predicting incident cardiovascular disease.

Lind L, Loader J, Lindahl B, Eggers K, Sundstrom J PLoS One. 2022; 17(7):e0271835.

PMID: 35877671 PMC: 9312363. DOI: 10.1371/journal.pone.0271835.

Serum High-Sensitivity Cardiac Troponin T as an Independent Predictor for Incident Coronary Heart Disease in the Japanese General Population: The Circulatory Risk in Communities Study (CIRCS).

Imano H, Yamagishi K, Ohira T, Kitamura A, Okada T, Muraki I J Atheroscler Thromb. 2022; 30(3):237-246.

PMID: 35569956 PMC: 9981345. DOI: 10.5551/jat.63378.

Circulating Ceramide: A New Cardiometabolic Biomarker in Patients With Comorbid Acute Coronary Syndrome and Type 2 Diabetes Mellitus.

Cao R, Fang Z, Li S, Xu M, Zhang J, Han D Front Physiol. 2020; 11:1104.

PMID: 33041846 PMC: 7522524. DOI: 10.3389/fphys.2020.01104.

References

Masson S, Anand I, Favero C, Barlera S, Vago T, Bertocchi F . Serial measurement of cardiac troponin T using a highly sensitive assay in patients with chronic heart failure: data from 2 large randomized clinical trials. Circulation. 2011; 125(2):280-8. DOI: 10.1161/CIRCULATIONAHA.111.044149. View

Rubin J, Matsushita K, Lazo M, Ballantyne C, Nambi V, Hoogeveen R . Determinants of minimal elevation in high-sensitivity cardiac troponin T in the general population. Clin Biochem. 2016; 49(9):657-662. PMC: 4889514. DOI: 10.1016/j.clinbiochem.2016.01.024. View

Oemrawsingh R, Cheng J, Garcia-Garcia H, Kardys I, van Schaik R, Regar E . High-sensitivity Troponin T in relation to coronary plaque characteristics in patients with stable coronary artery disease; results of the ATHEROREMO-IVUS study. Atherosclerosis. 2016; 247:135-41. DOI: 10.1016/j.atherosclerosis.2016.02.012. View

Kawasaki T, Sakai C, Harimoto K, Yamano M, Miki S, Kamitani T . Usefulness of high-sensitivity cardiac troponin T and brain natriuretic peptide as biomarkers of myocardial fibrosis in patients with hypertrophic cardiomyopathy. Am J Cardiol. 2013; 112(6):867-72. DOI: 10.1016/j.amjcard.2013.04.060. View

deFilippi C, de Lemos J, Christenson R, Gottdiener J, Kop W, Zhan M . Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults. JAMA. 2010; 304(22):2494-502. PMC: 3559101. DOI: 10.1001/jama.2010.1708. View

Scheven L, de Jong P, Hillege H, Lambers Heerspink H, van Pelt L, Kootstra J . High-sensitive troponin T and N-terminal pro-B type natriuretic peptide are associated with cardiovascular events despite the cross-sectional association with albuminuria and glomerular filtration rate. Eur Heart J. 2012; 33(18):2272-81. DOI: 10.1093/eurheartj/ehs163. View

Sacco R, Kasner S, Broderick J, Caplan L, Connors J, Culebras A . An updated definition of stroke for the 21st century: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013; 44(7):2064-89. PMC: 11078537. DOI: 10.1161/STR.0b013e318296aeca. View

Khot U, Khot M, Bajzer C, Sapp S, Ohman E, Brener S . Prevalence of conventional risk factors in patients with coronary heart disease. JAMA. 2003; 290(7):898-904. DOI: 10.1001/jama.290.7.898. View

Schnell-Inderst P, Schwarzer R, Gohler A, Grandi N, Grabein K, Stollenwerk B . Prognostic value, clinical effectiveness, and cost-effectiveness of high-sensitivity C-reactive protein as a marker for major cardiac events in asymptomatic individuals: a health technology assessment report. Int J Technol Assess Health Care. 2010; 26(1):30-9. DOI: 10.1017/S0266462309990870. View

10.

Luepker R, Apple F, Christenson R, Crow R, Fortmann S, Goff D . Case definitions for acute coronary heart disease in epidemiology and clinical research studies: a statement from the AHA Council on Epidemiology and Prevention; AHA Statistics Committee; World Heart Federation Council on Epidemiology and.... Circulation. 2003; 108(20):2543-9. DOI: 10.1161/01.CIR.0000100560.46946.EA. View

11.

Saunders J, Nambi V, de Lemos J, Chambless L, Virani S, Boerwinkle E . Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the Atherosclerosis Risk in Communities Study. Circulation. 2011; 123(13):1367-76. PMC: 3072024. DOI: 10.1161/CIRCULATIONAHA.110.005264. View

12.

Eggers K, Al-Shakarchi J, Berglund L, Lindahl B, Siegbahn A, Wallentin L . High-sensitive cardiac troponin T and its relations to cardiovascular risk factors, morbidity, and mortality in elderly men. Am Heart J. 2013; 166(3):541-8. DOI: 10.1016/j.ahj.2013.07.004. View

13.

Blankenberg S, Zeller T, Saarela O, Havulinna A, Kee F, Tunstall-Pedoe H . Contribution of 30 biomarkers to 10-year cardiovascular risk estimation in 2 population cohorts: the MONICA, risk, genetics, archiving, and monograph (MORGAM) biomarker project. Circulation. 2010; 121(22):2388-97. DOI: 10.1161/CIRCULATIONAHA.109.901413. View

14.

White H . Pathobiology of troponin elevations: do elevations occur with myocardial ischemia as well as necrosis?. J Am Coll Cardiol. 2011; 57(24):2406-8. DOI: 10.1016/j.jacc.2011.01.029. View

15.

Beatty A, Ku I, Christenson R, deFilippi C, Schiller N, Whooley M . High-sensitivity cardiac troponin T levels and secondary events in outpatients with coronary heart disease from the Heart and Soul Study. JAMA Intern Med. 2013; 173(9):763-9. PMC: 3719880. DOI: 10.1001/jamainternmed.2013.116. View

16.

Rosjo H, Andreassen J, Edvardsen T, Omland T . Prognostic usefulness of circulating high-sensitivity troponin T in aortic stenosis and relation to echocardiographic indexes of cardiac function and anatomy. Am J Cardiol. 2011; 108(1):88-91. DOI: 10.1016/j.amjcard.2011.02.346. View

17.

Daniels L, Clopton P, deFilippi C, Sanchez O, Bahrami H, Lima J . Serial measurement of N-terminal pro-B-type natriuretic peptide and cardiac troponin T for cardiovascular disease risk assessment in the Multi-Ethnic Study of Atherosclerosis (MESA). Am Heart J. 2015; 170(6):1170-83. PMC: 4684596. DOI: 10.1016/j.ahj.2015.09.010. View

18.

Hussein A, Bartz T, Gottdiener J, Sotoodehnia N, Heckbert S, Lloyd-Jones D . Serial measures of cardiac troponin T levels by a highly sensitive assay and incident atrial fibrillation in a prospective cohort of ambulatory older adults. Heart Rhythm. 2015; 12(5):879-85. PMC: 4546831. DOI: 10.1016/j.hrthm.2015.01.020. View

19.

Hussein A, Gottdiener J, Bartz T, Sotoodehnia N, deFilippi C, Dickfeld T . Cardiomyocyte injury assessed by a highly sensitive troponin assay and sudden cardiac death in the community: the Cardiovascular Health Study. J Am Coll Cardiol. 2013; 62(22):2112-20. PMC: 4157919. DOI: 10.1016/j.jacc.2013.07.049. View

20.

de Lemos J, Drazner M, Omland T, Ayers C, Khera A, Rohatgi A . Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. JAMA. 2010; 304(22):2503-12. PMC: 5621378. DOI: 10.1001/jama.2010.1768. View